Compare Ascendis Pharma A/S (ASND) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Li Auto Inc — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Li Auto Inc trades at $12.57 (market cap $12.54B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| ASND | LI | |
|---|---|---|
Market Cap | $16.78B | $12.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $26.69 |
52-Week Low | $189.74 | $11.74 |
Enterprise Value | $17.15B | $1.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
